
Introduction: Up to a half of patients after radical prostatectomy due to prostate cancer have biochemical recurrence, i.e., PSA concentrations >0.2 ng/ml. In most patients, biochemical recurrence does not significantly affect survival and quality of life; however, in about one third of patients, biochemical recurrence precedes a clinically relevant recurrence of prostate cancer. Usually, based on the current criteria of biochemical recurrence, prostate cancer recurrence is diagnosed several months after surgery. This delays adjuvant treatment and worsens treatment outcomes. This study aimed to check whether preoperative concentrations of markers of angiogenesis, lymphoangiogenesis, and extracellular matrix degradation could predict biochemical recurrence of prostate cancer after radical prostatectomy. Materials and methods: The study included 82 patients who underwent radical prostatectomy for prostate cancer (cT1-T2N0M0). Before surgery and 8-10 days after surgery, serum concentrations of PSA and markers of inflammatory processes, angiogenesis, lymphangiogenesis, and extracellular matrix degradation were measured (CRP, VEGF-A, VEGF-C, VEGF-D, TIMP-1, TIMP-2). The stage of prostate cancer was determined histopathologically (TNM classification, Gleason score) and clinically (digital rectal examination, prostate volume assed with ultrasound, pelvic magnetic resonance imaging). With the Kaplan-Meier analysis and Cox proportional hazard models, we checked whether the variables studied were associated with the risk of biochemical recurrence of prostate cancer after radical prostatectomy. Results: During a 3-year follow-up, 27 of 82 patients (32.9%) had biochemical recurrence of prostate cancer after radical prostatectomy. The risk of biochemical recurrence of prostate cancer was not significantly associated with patient age, BMI, result of preoperative prostate digital rectal examination, cancer stage assessed with pelvic magnetic resonance imaging, number of lymph nodes removed, and cancer grade on histopathology. The risk of biochemical recurrence of prostate cancer after radical prostatectomy was higher in patients with lower prostate volume on pre-operative transrectal ultrasound, higher Gleason score in preoperative and postoperative analyses, and positive surgical margins. The concentrations of the studied markers of inflammatory processes, angiogenesis, lymphangiogenesis, and remodeling of extracellular matrix were not related to the risk of biochemical recurrence of prostate cancer after radical prostatectomy.
Introduction: Taxanes especially paclitaxel is a key chemotherapeutic agent in the management of non-metastatic breast cancer. Different schedules are utilized in management with weekly paclitaxel being one of the common regimes. The weekly regimen has a distinctive toxicity profile. Methods: This retrospective study was done to study the adverse effect profile of weekly paclitaxel used in the treatment of non-metastatic breast cancer. Data were collected from case records of patients who received or were started on weekly paclitaxel single agent or in combination with trastuzumab between May and July 2019. Results: Eighty-eight patient case records were analyzed. The median age was 46.5 yrs (Range 30-67 yrs). The majority of patients received paclitaxel as an adjuvant (N=80, 91%). Sixty-one patients (69%) received single-agent paclitaxel while the remaining received it in combination with trastuzumab. Seventy-five percent (N=66) of patients did not have any modification of dosages in their regimen. Among those patients who required dose modification 19% (N=17) of patients required it from cycle 7 or beyond. Planned 12 cycles of weekly paclitaxel were completed in 81% (N=71) patients. The median duration for completion of 12 cycles from the start of chemotherapy was 80 days (Range 53-103). Major Grade 3/4 toxicities observed included peripheral neuropathy (12%) anemia (10%) and Neutropenia (4%). Conclusion: We observed a higher incidence of acute toxicities related to weekly paclitaxel though the majority of patients were able to complete their planned schedule of paclitaxel.
Childhood Chronic Myeloid Leukemia (CML) normally appears in adult group and its occurrence among children and particularly infants is very rare. Adult-Type CML (ATCML), which involves Philadelphia chromosome (Ph1); and commonly, presents with three important findings: huge splenomegaly, hyperleukocytosis and thrombocytosis. In this report, an infant with adult-type CML describes by detail without any common significant findings such as splenomegaly and thrombocytosis. This case is particularly attractive due to its very rare incidence in infancy, and the fact that it is presenting only with leukocytosis.
Background and Purpose: Phlebotomy has been broadly used as an assured and economical technique to tackle soft tissue lesions in ITM (Iranian Traditional Medicine), most Asian countries, Central Europe, and some parts of the US. In this study, phlebotomy was used for the treatment of Carpal Tunnel Syndrome (CTS) that is widely recognized as the most common neuropathy. This study aimed to investigate the effects of phlebotomy on the clinical and diagnostic findings of patients with CTS. Methods: This is a randomized clinical trial. For this analysis, an entire of 70 hands with CTS were studied, aged 20-60, and of every gender. The participants were divided into 2 groups: Control and Intervention. Within the control group, 35 were treated with a routine night splint for 3 months, and 35 patients in the intervention group, were received Fasd (Phlebotomy) of Osailem vein in addition to the routine night splint. The variables of which we evaluated were: pain, symptom severity, functional status, distal median nerve sensory latency, and distal median nerve motor latency. The pain has been evaluating by VAS Scale while the severity of symptoms and functional status of patients were evaluated by the Boston questionnaire, and the distal and motor nerve latency were evaluated through the diagnostic NCV test. Results: The results of the study demonstrated an incontestable improvement in symptom severity (P=0/0001) and functional status [Significant treatment effects for the Boston CTS- score (P=?0007)]. Additionally a serious decrease in Median nerve entrapment with NCV (p=0?015) of the intervention group in comparison with the control one. Pain severity of CTS symptoms (VAS), was also reduced significantly from 61.5 ± 20?5 to18.9 ± 15?7mm after 3 months in the phlebotomy group and from 67?1 ± 20?2 to 52?7 ± 21?8mm in the control group [group difference –33.8mm (P001). Conclusions: The results showed that the incorporation of phlebotomy (Fasd) treatment in an exceedingly routine therapy program would reduce the pain and symptom severity, improve the functional status of patients, and distal sensory and motor disturbance of the median nerve. Therefore, it is advised that phlebotomy (Fasd), as a convenient and low?cost complementary medicine technique could be employed within the treatment of CTS.
To study the efficacy, response of weekly cetuximab used concurrently with radiotherapy versus weekly cisplatin with concurrent radiotherapy in loco regionally advanced Head and Neck Squamous Cell Carcinoma (HNSCC). Materials and Methods: Fifty eligible patients were randomly assigned to study arm (Cetuximab arm) and control arm (Cisplatin arm) to receive either intravenous cetuximab 400 mg/m2 or weekly intravenous cisplatin 40 mg/ m2, during RT. RT dose received was 70Gy in 35 fractions with 2Gy/fraction in both the arms. Treatment evaluation was done by assessing tumor response after 6 months follow up period after completion of chemo radiotherapy. Results: Overall Response (OR) rates, which include Complete response (CR) and Partial Response (PR), were assessed in all the treated patients of locally advanced HNSCC at 6 months after completion of treatment. 76% overall response was achieved (CR-56%+PR-20%) in cetuximab arm and 80%(CR52%+PR-28%) in Cisplatin arm (p=1.000). Conclusion: Weekly Cisplatin shows slightly better results in terms of overall response comparing to weekly Cetuximab in our study. Large sample size and longer duration of follow up are needed for strong evaluation of efficacy, to draw inferences on Loco regional Control (LRC) Disease Free Survival (DFS) and Overall Survival (OS).